Latest Intercell Stories
Reportbuyer.com just published a new market research report:
Statens Serum Institut and Aeras today announced the initiation of the first Phase I clinical trial of a new candidate TB vaccine designed to protect people latently infected with TB from developing active TB disease.
VIENNA, May 10, 2011 /PRNewswire/ -- Today, the biotech-vaccine company Intercell AG (VSE: ICLL) announced its financial results for Q1 and presented an update on the Company's development programs. Financial Results Year-on-year revenue growth of 19.7% driven by strong IXIAROÂ®/JESPECTÂ® sales revenues Restructuring process progressing successfully - operating loss reduced by 33.1%Higher sales and reduced spending lead to reduced net loss of EUR 11.3mCash position of EUR 87.7m at...
VIENNA, May 5, 2011 /PRNewswire/ -- Today Intercell AG (VSE: ICLL) announced that the company's Supervisory Board has appointed Thomas Lingelbach as new Chief Executive Officer (CEO) for Intercell, effective May 10, 2011.
WHITEHOUSE STATION, N.J., and VIENNA, April 11, 2011 /PRNewswire/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Intercell AG (VSE: ICLL) today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S.
VIENNA, April 1, 2011 /PRNewswire/ -- Today Intercell AG (VSE: ICLL) announced that it has agreed with Novartis to advance Intercell's investigational Pseudomonas aeruginosa vaccine into a confirmatory clinical efficacy trial in ventilated ICU (Intensive Care Unit) patients.
VIENNA, March 1, 2011 /PRNewswire/ -- Today Intercell AG (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2010 and presented an update on the Company's development programs. Increase in IXIAROÂ®/JESPECTÂ® sales by approximately 66% to EUR 12.8m for the full year 2010, due to increased sales in key travel markets and to U.S.
VIENNA, Feb. 22, 2011 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced the offering of EUR 30.8m of Senior Unsecured Convertible Notes (the "Notes").
- In Roman antiquity, the return of a person who had been banished, or taken prisoner by an enemy, to his old condition and former privileges.
- In international law, that right by virtue of which persons and things taken by an enemy in war are restored to their former status when coming again under the power of the nation to which they belonged.